The Filing Desk

Fate Therapeutics vs Korro Bio

Fate Therapeutics FATE · Korro Bio KRRO · Biotechnology

Fate Therapeutics reported revenue of $7 million in fiscal 2025, about the same as Korro Bio's $6 million in fiscal 2025. Fate Therapeutics' revenue fell 51.2% in its latest year, and Korro Bio's grew 181.5%. Fate Therapeutics had an operating margin of -2222.4%, against -1906.4% at Korro Bio. Free cash flow was −$112 million at Fate Therapeutics and −$79 million at Korro Bio.

Side by side

Fate TherapeuticsKorro Bio
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$7M$6M
Revenue growth−51.2%181.5%
Revenue growth a year, last 5 years−26.8%−29.6%
Gross margin——
Operating margin−2,222.4%−1,906.4%
Net margin−2,051.1%−1,834.5%
Free cash flow−$112M−$79M
Free cash flow margin−1,685.8%−1,237.2%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count4.5%5.3%
Last close$1.01$12.19
P/E at the last close——
Insider trades, last 12 monthssold $322,862bought $2.4 million, sold $5.7 million
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Fate TherapeuticsKorro Bio
Operating margin
Percent of revenue
Fate TherapeuticsKorro Bio
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Fate TherapeuticsKorro Bio

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Fate Therapeutics and Korro Bio pages.